(VCEL) Vericel Ord - Ratings and Ratios

Vericel Corporation, a commercial-stage biopharmaceutical company, specializes in the research, development, and commercialization of advanced cellular therapies and specialty biologic products. Its primary focus is on addressing unmet medical needs in sports medicine and severe burn care within North America. The companys product portfolio includes MACI, an autologous cultured chondrocytes on porcine collagen membrane designed for the repair of symptomatic cartilage defects in the knee; Epicel, a permanent skin replacement solution for patients with severe burns; and NexoBrid, a topical biological product for eschar removal in burn injuries. Vericels products are supported by robust clinical data and regulatory approvals, including humanitarian use designation for Epicel and orphan product status for NexoBrid. The companys commitment to innovation and patient outcomes has established it as a leader in the field of regenerative medicine.

Originally founded in 1989 as Aastrom Biosciences, Inc., the company rebranded as Vericel Corporation in November 2014 to reflect its expanded focus and strategic direction. Headquartered in Cambridge, Massachusetts, Vericel operates at the intersection of advanced biotechnology and medical devices, leveraging its expertise in cell therapy to improve patient care. Its products are used by healthcare professionals in orthopedic and burn treatment centers across North America. For more information, visit: https://www.vcel.com.

3-Month Forecast: Based on and , VCEL is expected to face near-term volatility. The stock is currently trading below its 20, 50, and 200-day moving averages, indicating bearish momentum. The average true range (ATR) of 2.30 suggests moderate volatility. However, the companys high price-to-earnings (P/E) ratio of 206.15 and forward P/E of 114.94 reflect market expectations for future growth. With a market capitalization of $2.067 billion and a price-to-sales (P/S) ratio of 8.71, VCEL is positioned as a high-growth biotechnology firm. Over the next three months, the stock may experience continued pressure due to its elevated valuation multiples, but strong fundamental performance could stabilize or drive upward momentum.